Literature DB >> 18246529

XRCC4 codon 247*A and XRCC4 promoter -1394*T related genotypes but not XRCC4 intron 3 gene polymorphism are associated with higher susceptibility for endometriosis.

Yao-Yuan Hsieh1, Da-Tian Bau, Chi-Chen Chang, Chang-Hai Tsai, Chih-Ping Chen, Fuu-Jen Tsai.   

Abstract

DNA repair systems act to maintain genome integrity in the face of replication errors, environmental insults, and the cumulative effects of age. Genetic variants in DNA repair genes such as X-ray repair cross-complementing group 4 (XRCC4) might influence the ability to repair damaged DNA. Herein we aimed to investigate whether some XRCC4-related polymorphisms were associated with endometriosis susceptibility. Women were divided: (1) severe endometriosis (rAFS stage IV, n = 136) and (2) nonendometriosis groups (n = 112). The polymorphisms of XRCC4 codon 247, XRCC4 promoter -1394, and XRCC4 intron 3 insertion/deletion (I/D) polymorphism were amplified by PCR and detected by electrophoresis after restriction enzyme (BBS I, Hinc II) digestions. Genotypes and allelic frequencies in both groups were compared. We observed that XRCC4 codon 247*A and XRCC4 promoter -1394*T related genotypes, but not XRCC4 intron 3 I/D polymorphism, are associated with higher susceptibility for endometriosis. Distributions of XRCC4 codon 247*C homozygote/heterozygote/A homozygote, and C/A allele in both groups were: (1) 89/9.5/1.5% and 93.7/6.3%; (2) 97.3/2.7/0%, and 98.7/1.3% (P < 0.05). Proportions of XRCC4 promoter -1394*T homozygote/heterozygote/G homozygote and T/G allele in both groups were: (1) 94.1/5.2/0.7% and 96.7/3.3%, and (2) 79.4/17.9/2.7% and 88.4/11.6% (P < 0.005). Proportions of XRCC4*I homozygote/heterozygote/D homozygote and A/C allele in both groups were: (1) 67.6/30.9/1.5% and 83.2/16.8%, and (2) 70.5/24.1/5.4% and 82.6/17.4% (nondifference). We conclude that XRCC4 codon 247*A and XRCC4 promoter -1394*T related genotypes and alleles, but not XRCC4 intron 3 I/D polymorphism, might be associated with endometriosis susceptibilities and pathogenesis. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18246529     DOI: 10.1002/mrd.20829

Source DB:  PubMed          Journal:  Mol Reprod Dev        ISSN: 1040-452X            Impact factor:   2.609


  6 in total

1.  Association of XRCC3 and XRCC4 gene polymorphisms, family history of cancer and tobacco smoking with non-small-cell lung cancer in a Chinese population: a case-control study.

Authors:  Fei He; Shen-Chih Chang; Gina Maria Wallar; Zuo-Feng Zhang; Lin Cai
Journal:  J Hum Genet       Date:  2013-08-08       Impact factor: 3.172

2.  The current progress and future prospects of personalized radiogenomic cancer study.

Authors:  Juhn-Cherng Liu; Wu-Chung Shen; Tzu-Ching Shih; Chia-Wen Tsai; Wen-Shin Chang; Der-Yang Cho; Chang-Hai Tsai; Da-Tian Bau
Journal:  Biomedicine (Taipei)       Date:  2015-02-02

3.  Susceptibility to Breast Cancer and Intron 3 Ins/Del Genetic Polymorphism of DNA Double-Strand Break Repair Gene XRCC4.

Authors:  Mostafa Saadat; Shekoofeh Saadat
Journal:  J Med Biochem       Date:  2015-09-19       Impact factor: 3.402

4.  The role of IL‑16 gene polymorphisms in endometriosis.

Authors:  Michail Matalliotakis; Maria I Zervou; Elias Eliopoulos; Charoula Matalliotaki; Nilufer Rahmioglu; Ioannis Kalogiannidis; Krina Zondervan; Demetrios A Spandidos; Ioannis Matalliotakis; George N Goulielmos
Journal:  Int J Mol Med       Date:  2018-01-09       Impact factor: 4.101

Review 5.  A review of the risk factors, genetics and treatment of endometriosis in Chinese women: a comparative update.

Authors:  Yi Dai; Xiaoyan Li; Jinghua Shi; Jinhua Leng
Journal:  Reprod Health       Date:  2018-05-21       Impact factor: 3.223

6.  The role of gene polymorphisms in endometriosis.

Authors:  Michail Matalliotakis; Maria I Zervou; Charoula Matalliotaki; Nilufer Rahmioglu; George Koumantakis; Ioannis Kalogiannidis; Ioannis Prapas; Krina Zondervan; Demetrios A Spandidos; Ioannis Matalliotakis; George N Goulielmos
Journal:  Mol Med Rep       Date:  2017-08-29       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.